Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing

worldpharmanewsJuly 18, 2017

Tag: Novartis , psoriasis , fully-human IL-17A

PharmaSources Customer Service